

The Antiviral Program for Pandemics at NCATS-NIH

Philip Sanderson, NIH

The US Government's Antiviral Program for Pandemics (APP) was launched in June 2021 with funding and a mandate to develop next generation COVID-19 treatments and to prepare for future virus threats. The APP provides in kind support and funding from NIAID, NCATS and BARDA for the discovery and early development of direct acting antivirals against seven priority virus families, through Phase I clinical trials. The antivirals should be easy to administer, preferably orally when feasible, and widely available. Peptide and oligonucleotide therapeutics are in scope. Host directed therapies, repurposed marketed therapies, and antibodies are out of scope. This presentation will summarize the different components of APP, and will provide specific examples of NCATS activities.